查看文章

Study Objective. To determine whether the pharmacokinetics of atazanavir, a protease inhibitor used to treat human immunodeficiency virus (HIV) infection, are altered by its coadministration with lansoprazole, a proton pump inhibitor.

Design. Single‐dose, open‐label, complete‐crossover study.

Setting. Clinical research center.

Subjects. Ten healthy adult volunteers.

Measurements and Main Results. In phase A, subjects received a single oral dose of atazanavir 400 mg alone. In phase B, the same subjects received oral lansoprazole 60 mg, and after 24 hours they were given a second dose of oral lansoprazole 60 mg with atazanavir 400 mg. Eleven blood samples were collected from each subject over a 24‐hour period for determination of atazanavir plasma concentrations by a validated high‐performance liquid chromatography assay. Pharmacokinetic analysis was performed by standard noncompartmental …